Moving T-DXd Into Earlier HER2-Positive Breast Cancer Care

— Jame Abraham, MD, discusses how DESTINY-Breast11 may reshape care

by Gregory Laub, Senior Director, Video, MedPage Today

June 16, 2026

• 2 min read

At the American Society of Clinical Oncology (ASCO) annual meeting, results from the DESTINY-Breast11 trial showed higher pathologic complete response (pCR) rates with a trastuzumab deruxtecan (T-DXd; Enhertu)-based neoadjuvant regimen compared with standard anthracycline-containing therapy in patients with high-risk HER2-positive early breast cancer.